Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423445 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL504375 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8653995 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL8948482 | 1.00 | AKR1B1 (0.38) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Hydrochloric Acid SCHEMBL15779291 | 0.97 | AKR1B1 (0.36) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| Phosphoric Acid SCHEMBL5789491 | 0.91 | MPI (0.39) | AKR1B1LMNAL3MBTL1MPI | |
| SCHEMBL5699947 | 0.85 | AKR1B1 (0.43) | AKR1B1 | |
| SCHEMBL17984936 | 0.85 | HIF1A (0.41) | AKR1B1LMNAL3MBTL1TDP1HIF1A | |
| SCHEMBL17984952 | 0.85 | LMNA (0.46) | AKR1B1LMNAL3MBTL1TDP1PDE4A | |
| SCHEMBL17984927 | 0.84 | THRB (0.33) | AKR1B1HIF1AMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102603815-A | Deoxysugar and preparation method of the deoxysugar | UNIV FUDAN | 2012-07-25 | — | — | CN | claimed |
| EP-2150620-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES, AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSE DERIVATIVES | Libragen (FR) | 2010-02-10 | — | — | EP | claimed |
| WO-2008142155-A2 | METHOD FOR PREPARING C-6 PHOSPHORYLATED D-ALDOHEXOSES AND C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES AND NEW C-6 PHOSPHORYLATED D-ALDOHEXOSES DERIVATIVES | LIBRAGEN (FR) | 2008-11-27 | — | — | WO | claimed |
| EP-1995323-A1 | Method for preparing C-6 phosphorylated D-aldohexoses and C-6 phosphorylated D-aldohexose derivatives | Libragen (FR) | 2008-11-26 | — | — | EP | claimed |
| EP-0739333-B1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | DU PONT (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0739333-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-10-30 | — | — | EP | claimed |
| US-5510470-A | CONTAINS A DIDEOXYSACCHARIDE; USED WITH ZERO VALENT NICKEL AS A CATALYST FOR ENANTIOSELECTIVE HYDROCYANATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | claimed |
| US-5510507-A | COORDINATION CATALYSTS; EFFICIENT ENANTIOSELECTIVITY | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-04-23 | — | — | US | claimed |
| US-5484902-A | HYDROCYANATION OF VINYL AROMATICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-16 | — | — | US | claimed |
| US-5481006-A | PREPARATION OF INTERMEDIATES FOR PHARMACEUTICALS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| WO-1995018787-A1 | SELECTIVE ASYMMETRIC HYDROGENATION OF DEHYDROAMINO ACID DERIVATIVES USING RHODIUM AND IRIDIUM DIPHOSPHINITE CARBOHYDRATE CATALYST COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-07-13 | — | — | WO | claimed |
| US-8722864-B2 | Glycosylated acetaminophen pro-drug analogs | NuTek Pharma Ltd. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | NuTek Pharma Ltd. | 2013-08-22 | — | — | US | disclosed |
| US-20120231972-A1 | Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same | INSTITUTE OF CATALYSIS (CSIC) (ES) | 2012-09-13 | — | — | US | disclosed |
| CN-102603815-A | Deoxysugar and preparation method of the deoxysugar | UNIV FUDAN | 2012-07-25 | — | — | CN | disclosed |
| US-RE31512-E | SISOMICIN BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1984-01-31 | — | — | US | disclosed |
| US-4235888-A | SISOMYCIN-TYPE ANTIBIOTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-25 | — | — | US | disclosed |
| EP-0007996-A1 | 4,6-Di-0-(Aminoglycosyl)-1,3-diaminocyclitols, process for their preparation and pharmaceutical compositions containing them | BAYER AG (DE) | 1980-02-20 | — | — | EP | disclosed |
| US-4065557-A | GLUCOPYRANOSE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-27 | — | — | US | disclosed |
| US-4062950-A | SACCHARASE AND AMYLASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120231972-A1 | Probe Compound for Detecting and Isolating Enzymes and Means and Methods Using the Same | SI, GUSB, MPI | AKR1B1 92/4885LMNA 2150/4885L3MBTL1 2173/4885 |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | UGT1A3, GCG, UGGT1 | AKR1B1 451/4885LMNA 1464/4885L3MBTL1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.